{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:11:57Z","timestamp":1782918717002,"version":"3.54.5"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82103221"],"award-info":[{"award-number":["82103221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072714"],"award-info":[{"award-number":["82072714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972263"],"award-info":[{"award-number":["81972263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2020M683094"],"award-info":[{"award-number":["2020M683094"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Excellent Young Talent Program of Guangdong Provincial People's Hospital","award":["KY012021190"],"award-info":[{"award-number":["KY012021190"]}]},{"name":"the High-level Hospital Construction Project","award":["DFJH201921"],"award-info":[{"award-number":["DFJH201921"]}]},{"name":"the program of Guangdong Provincial Clinical Research Center for Digestive Diseases","award":["2020B1111170004"],"award-info":[{"award-number":["2020B1111170004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13402-024-00921-1","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T13:02:21Z","timestamp":1707138141000},"page":"1205-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma"],"prefix":"10.1007","volume":"47","author":[{"given":"Hongkai","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zedan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A. Villanueva","year":"2019","unstructured":"A. Villanueva, Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450\u20131462 (2019)","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"921_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/hep.31175","volume":"73","author":"J.C. Nault","year":"2021","unstructured":"J.C. Nault, A. Villanueva, Biomarkers for hepatobiliary cancers. Hepatology 73(Suppl 1), 115\u2013127 (2021)","journal-title":"Hepatology"},{"key":"921_CR3","doi-asserted-by":"crossref","unstructured":"U. Harkus et al., Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin. Cancer Biol. 86, 799\u2013815 (2022)","DOI":"10.1016\/j.semcancer.2022.01.005"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/hep.31706","volume":"73","author":"S.M. Kalasekar","year":"2021","unstructured":"S.M. Kalasekar, I. Garrido-Laguna, K.J. Evason, Immune checkpoint inhibitors in combinations for hepatocellular carcinoma. Hepatology 73, 2591\u20132593 (2021)","journal-title":"Hepatology"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A. Huang","year":"2020","unstructured":"A. Huang, et al., Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target Ther. 5, 146 (2020)","journal-title":"Signal Transduct. Target Ther."},{"key":"921_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","volume":"70","author":"M. Pinter","year":"2021","unstructured":"M. Pinter, B. Scheiner, M. Peck-Radosavljevic, Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 70, 204\u2013214 (2021)","journal-title":"Gut"},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/gutjnl-2019-319658","volume":"69","author":"E.N. De Toni","year":"2020","unstructured":"E.N. De Toni, Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut 69, 1887\u20131888 (2020)","journal-title":"Gut"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"T.F. Greten","year":"2019","unstructured":"T.F. Greten, et al., Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology 156, 510\u2013524 (2019)","journal-title":"Gastroenterology"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K. Shigeta","year":"2020","unstructured":"K. Shigeta, et al., Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247\u20131261 (2020)","journal-title":"Hepatology"},{"key":"921_CR10","doi-asserted-by":"crossref","unstructured":"K. Shigeta, et al., Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J. Immunother. Cancer 8, e001435 (2020)","DOI":"10.1136\/jitc-2020-001435"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","volume":"27","author":"S.J. Casak","year":"2021","unstructured":"S.J. Casak, et al., FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin. Cancer. Res. 27, 1836\u20131841 (2021)","journal-title":"Clin. Cancer. Res."},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S. Qin","year":"2019","unstructured":"S. Qin, et al., Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J. Hematol. Oncol. 12, 27 (2019)","journal-title":"J. Hematol. Oncol."},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-07-0682","volume":"13","author":"M.E. Couch","year":"2007","unstructured":"M.E. Couch, et al., Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin. Cancer. Res. 13, 7199\u20137206 (2007)","journal-title":"Clin. Cancer. Res."},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E. Dai","year":"2021","unstructured":"E. Dai, et al., Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol. Cancer 20, 171 (2021)","journal-title":"Mol. Cancer"},{"key":"921_CR15","doi-asserted-by":"crossref","unstructured":"X.M. Shao, et al., HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Ann. Oncol. 33, 728\u2013738 (2022)","DOI":"10.1016\/j.annonc.2022.03.013"},{"key":"921_CR16","doi-asserted-by":"crossref","unstructured":"S.E. Lee, et al., Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer Immunol. Immunother. 71, 1\u201314 (2022)","DOI":"10.1007\/s00262-022-03220-6"},{"key":"921_CR17","doi-asserted-by":"crossref","unstructured":"E.B. Ellingsen, et al., Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. J. Immunother. Cancer 10, e004345 (2022)","DOI":"10.1136\/jitc-2021-004345"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-022-01290-8","volume":"15","author":"A. Rooney","year":"2022","unstructured":"A. Rooney, et al., Risk of SARS-CoV-2 breakthrough infection in vaccinated cancer patients: a retrospective cohort study. J. Hematol. Oncol. 15, 67 (2022)","journal-title":"J. Hematol. Oncol."},{"key":"921_CR19","doi-asserted-by":"crossref","unstructured":"E. Fang, et al., Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target Ther. 7, 94 (2022)","DOI":"10.1038\/s41392-022-00950-y"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S. Qin","year":"2022","unstructured":"S. Qin, et al., mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target Ther. 7, 166 (2022)","journal-title":"Signal Transduct. Target Ther."},{"key":"921_CR21","doi-asserted-by":"crossref","unstructured":"W. Mey, et al., RNA in cancer immunotherapy: unlocking the potential of the immune system. Clin. Cancer. Res. 28, 3929\u20133939 (2022)","DOI":"10.1158\/1078-0432.CCR-21-3304"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"102405","DOI":"10.1016\/j.ctrv.2022.102405","volume":"107","author":"J. Wei","year":"2022","unstructured":"J. Wei, A.M. Hui, The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines. Cancer Treat. Rev. 107, 102405 (2022)","journal-title":"Cancer Treat. Rev."},{"key":"921_CR23","doi-asserted-by":"crossref","unstructured":"A.J. Barbier, et al., The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022)","DOI":"10.1038\/s41587-022-01294-2"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"922301","DOI":"10.3389\/fimmu.2022.922301","volume":"13","author":"T. Huang","year":"2022","unstructured":"T. Huang, et al., Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front. Immunol. 13, 922301 (2022)","journal-title":"Front. Immunol."},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"C.L. Lorentzen","year":"2022","unstructured":"C.L. Lorentzen, et al., Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450\u2013e458 (2022)","journal-title":"Lancet Oncol."},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N. Pardi","year":"2018","unstructured":"N. Pardi, et al., mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018)","journal-title":"Nat. Rev. Drug Discov."},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/1471-2407-14-748","volume":"14","author":"M. Sebastian","year":"2014","unstructured":"M. Sebastian, et al., Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14, 748 (2014)","journal-title":"BMC Cancer"},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","volume":"23","author":"K.A. Batich","year":"2017","unstructured":"K.A. Batich, et al., Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin. Cancer. Res. 23, 1898\u20131909 (2017)","journal-title":"Clin. Cancer. Res."},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/ijc.28482","volume":"134","author":"J. Li","year":"2014","unstructured":"J. Li, et al., Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int. J. Cancer 134, 1683\u20131694 (2014)","journal-title":"Int. J. Cancer"},{"key":"921_CR30","doi-asserted-by":"crossref","unstructured":"H. Kubler, et al., Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study. J. Immunother. Cancer 3, 26 (2015)","DOI":"10.1186\/s40425-015-0068-y"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z. Tang","year":"2019","unstructured":"Z. Tang, et al., GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic. Acids Res. 47, W556\u2013W560 (2019)","journal-title":"Nucleic. Acids Res."},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T. Li","year":"2017","unstructured":"T. Li, et al., TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108\u2013e110 (2017)","journal-title":"Cancer Res."},{"key":"921_CR33","doi-asserted-by":"crossref","unstructured":"S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013)","DOI":"10.1186\/1471-2105-14-7"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G. Bindea","year":"2013","unstructured":"G. Bindea, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013)","journal-title":"Immunity"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P. Charoentong","year":"2017","unstructured":"P. Charoentong, et al., Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017)","journal-title":"Cell Rep."},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K. Yoshihara","year":"2013","unstructured":"K. Yoshihara, et al., Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013)","journal-title":"Nat. Commun."},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"e88309","DOI":"10.1371\/journal.pone.0088309","volume":"9","author":"D.M. Wolf","year":"2014","unstructured":"D.M. Wolf, et al., Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One 9, e88309 (2014)","journal-title":"PLoS One"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P. Langfelder","year":"2008","unstructured":"P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 9, 559 (2008)","journal-title":"BMC Bioinf."},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"D793","DOI":"10.1093\/nar\/gks1055","volume":"41","author":"A. Kamburov","year":"2013","unstructured":"A. Kamburov, et al., The consensusPathDB interaction database: 2013 update. Nucleic. Acids Res. 41, D793\u2013800 (2013)","journal-title":"Nucleic. Acids Res."},{"key":"921_CR40","doi-asserted-by":"crossref","unstructured":"X. Huang, et al., Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol. Cancer 20, 44 (2021)","DOI":"10.1186\/s12943-021-01310-0"},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"R.L. Camp","year":"2004","unstructured":"R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer. Res. 10, 7252\u20137259 (2004)","journal-title":"Clin. Cancer. Res."},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"1902880","DOI":"10.1002\/advs.201902880","volume":"7","author":"Y.R. Miao","year":"2020","unstructured":"Y.R. Miao, et al., ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv. Sci. (Weinh) 7, 1902880 (2020)","journal-title":"Adv. Sci. (Weinh)"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G. Zhang","year":"2023","unstructured":"G. Zhang, et al., mRNA vaccines in disease prevention and treatment. Signal Transduct. Target Ther. 8, 365 (2023)","journal-title":"Signal Transduct. Target Ther."},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","volume":"20","author":"X. Huang","year":"2021","unstructured":"X. Huang, et al., Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol. Cancer 20, 50 (2021)","journal-title":"Mol. Cancer"},{"key":"921_CR45","doi-asserted-by":"crossref","unstructured":"X. Huang, et al., Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil. Med. Res. 9, 53 (2022)","DOI":"10.1186\/s40779-022-00416-w"},{"key":"921_CR46","doi-asserted-by":"crossref","unstructured":"T.Y. Tang, et al., mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil. Med. Res. 9, 40 (2022)","DOI":"10.1186\/s40779-022-00399-8"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.tips.2022.03.005","volume":"43","author":"X. Huang","year":"2022","unstructured":"X. Huang, G. Zhang, T. Liang, Subtyping for pancreatic cancer precision therapy. Trends Pharmacol. Sci. 43, 482\u2013494 (2022)","journal-title":"Trends Pharmacol. Sci."},{"key":"921_CR48","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s42003-020-01367-5","volume":"3","author":"J. Seo","year":"2020","unstructured":"J. Seo, et al., Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun. Biol. 3, 638 (2020)","journal-title":"Commun. Biol."},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2159-8290.CD-18-0706","volume":"9","author":"V.W. Rebecca","year":"2019","unstructured":"V.W. Rebecca, et al., PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov. 9, 220\u2013229 (2019)","journal-title":"Cancer Discov."},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12935-022-02508-y","volume":"22","author":"J. Xu","year":"2022","unstructured":"J. Xu, et al., High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer Cell Int. 22, 115 (2022)","journal-title":"Cancer Cell Int."},{"key":"921_CR51","doi-asserted-by":"crossref","unstructured":"G. Sharma, et al., PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. JCI Insight 5, e133225 (2020)","DOI":"10.1172\/jci.insight.133225"},{"key":"921_CR52","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","volume":"19","author":"S. He","year":"2018","unstructured":"S. He, X. Wang, RIP kinases as modulators of inflammation and immunity. Nat. Immunol. 19, 912\u2013922 (2018)","journal-title":"Nat. Immunol."},{"key":"921_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41467-022-28340-6","volume":"13","author":"Y. Yan","year":"2022","unstructured":"Y. Yan, et al., Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nat. Commun. 13, 669 (2022)","journal-title":"Nat. Commun."},{"key":"921_CR54","doi-asserted-by":"crossref","unstructured":"Y. Zhou, et al., Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J. Hematol. Oncol. 14, 9 (2021)","DOI":"10.1186\/s13045-020-01028-4"},{"key":"921_CR55","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-07-6484","volume":"68","author":"M.J. Gough","year":"2008","unstructured":"M.J. Gough, et al., OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68, 5206\u20135215 (2008)","journal-title":"Cancer Res."},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1053\/j.seminoncol.2010.09.013","volume":"37","author":"S.M. Jensen","year":"2010","unstructured":"S.M. Jensen, et al., Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 37, 524\u2013532 (2010)","journal-title":"Semin. Oncol."},{"key":"921_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-065X.2011.01069.x","volume":"244","author":"A.D. Weinberg","year":"2011","unstructured":"A.D. Weinberg, et al., Science gone translational: the OX40 agonist story. Immunol. Rev. 244, 218\u2013231 (2011)","journal-title":"Immunol. Rev."},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2015.11.009","volume":"52","author":"R.B. Bell","year":"2016","unstructured":"R.B. Bell, et al., OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment. Oral. Oncol. 52, 1\u201310 (2016)","journal-title":"Oral. Oncol."},{"key":"921_CR59","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","volume":"12","author":"R. Duhen","year":"2021","unstructured":"R. Duhen, et al., Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat. Commun. 12, 1047 (2021)","journal-title":"Nat. Commun."},{"key":"921_CR60","doi-asserted-by":"publisher","first-page":"36824","DOI":"10.1021\/acsami.1c08201","volume":"13","author":"Q. Song","year":"2021","unstructured":"Q. Song, et al., Reinforcing the combinational immuno-oncotherapy of switching \u201ccold\u201d tumor to \u201chot\u201d by responsive penetrating nanogels. ACS Appl. Mater. Interf. 13, 36824\u201336838 (2021)","journal-title":"ACS Appl. Mater. Interf."},{"key":"921_CR61","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-21-1382","volume":"82","author":"W.X. Hong","year":"2022","unstructured":"W.X. Hong, et al., Neoadjuvant intratumoral immunotherapy with TLR9 activation and anti-OX40 antibody eradicates metastatic cancer. Cancer Res. 82, 1396\u20131408 (2022)","journal-title":"Cancer Res."},{"key":"921_CR62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","volume":"31","author":"A.M. Boutelle","year":"2021","unstructured":"A.M. Boutelle, L.D. Attardi, p53 and tumor suppression: it takes a network. Trends. Cell Biol. 31, 298\u2013310 (2021)","journal-title":"Trends. Cell Biol."},{"key":"921_CR63","doi-asserted-by":"publisher","first-page":"R527","DOI":"10.1016\/j.cub.2013.04.076","volume":"23","author":"N. Raj","year":"2013","unstructured":"N. Raj, L.D. Attardi, Tumor suppression: p53 alters immune surveillance to restrain liver cancer. Curr. Biol. 23, R527\u2013530 (2013)","journal-title":"Curr. Biol."},{"key":"921_CR64","doi-asserted-by":"publisher","first-page":"237ra267","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"S.L. Highfill","year":"2014","unstructured":"S.L. Highfill, et al., Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra267 (2014)","journal-title":"Sci. Transl. Med."},{"key":"921_CR65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-019-1047-6","volume":"18","author":"C. Lu","year":"2019","unstructured":"C. Lu, et al., Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol. Cancer 18, 130 (2019)","journal-title":"Mol. Cancer"},{"key":"921_CR66","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2018.10.040","volume":"70","author":"S.J. Yu","year":"2019","unstructured":"S.J. Yu, et al., Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J. Hepatol. 70, 449\u2013457 (2019)","journal-title":"J. Hepatol."},{"key":"921_CR67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C. Groth","year":"2019","unstructured":"C. Groth, et al., Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16\u201325 (2019)","journal-title":"Br. J. Cancer"},{"key":"921_CR68","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","volume":"73","author":"S. Kalathil","year":"2013","unstructured":"S. Kalathil, et al., Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 73, 2435\u20132444 (2013)","journal-title":"Cancer Res."},{"key":"921_CR69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B. Hoechst","year":"2009","unstructured":"B. Hoechst, et al., Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799\u2013807 (2009)","journal-title":"Hepatology"},{"key":"921_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R. Derynck","year":"2021","unstructured":"R. Derynck, S.J. Turley, R.J. Akhurst, TGFbeta biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"921_CR71","doi-asserted-by":"publisher","first-page":"e1257453","DOI":"10.1080\/2162402X.2016.1257453","volume":"6","author":"A. de Gramont","year":"2017","unstructured":"A. de Gramont, S. Faivre, E. Raymond, Novel TGF-beta inhibitors ready for prime time in onco-immunology. Oncoimmunology 6, e1257453 (2017)","journal-title":"Oncoimmunology"},{"key":"921_CR72","doi-asserted-by":"crossref","unstructured":"J. Cullis, S. Das, D. Bar-Sagi, Kras and tumor immunity: friend or foe? Cold Spring Harb. Perspect. Med. 8, a031849 (2018)","DOI":"10.1101\/cshperspect.a031849"},{"key":"921_CR73","doi-asserted-by":"crossref","unstructured":"J. Chen, J.A. Gingold, X. Su, Immunomodulatory TGF-beta signaling in hepatocellular carcinoma. Trends Mol. Med. 25, 1010\u20131023 (2019)","DOI":"10.1016\/j.molmed.2019.06.007"},{"key":"921_CR74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"S.C. Casey","year":"2016","unstructured":"S.C. Casey, et al., MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016)","journal-title":"Science"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00921-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-024-00921-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00921-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:20:56Z","timestamp":1723569656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-024-00921-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s13402-024-00921-1","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"16 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All datasets are freely available as public resources. Therefore, local ethics approval was not required. Two tumor arrays with tumor and adjacent tumor samples from 90 HCC patients (HLivH180Su09-T-001 and HLivH180Su09-T-002) were purchased from Shanghai Outdo Biotech (Co. Ltd., Shanghai, China.). All tissues were collected according to the ethical standards from Shanghai Outdo Biotech (No.: SHYJS-CP-1607007). And informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}